The assessment of quality of life in clinical practice in patients with schizophrenia

Dialogues in Clinical Neuroscience

Volumn 16, Issue 2, 2014, Pages 185-195

  Karow, Anne ^a   Wittmann, Linus ^a   Schöttle, Daniel ^a   Schäfer, Ingo ^a   Lambert, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotic; Assertive community treatment; Integrative care; Quality of life; Remission; Schizophrenia; Symptom

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; BEHAVIOR THERAPY; CLINICAL PRACTICE; COGNITIVE DEFECT; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; EMOTIONAL DISORDER; FUNCTIONAL DISEASE; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MEDICAL EDUCATION; MEDLINE; NEGATIVE SYNDROME; PHYSICAL ACTIVITY; PHYSIOTHERAPY; POSITIVE SYNDROME; PSYCHOEDUCATION; QUALITY OF LIFE; REMISSION; SCHIZOPHRENIA; TREATMENT RESPONSE; COGNITION DISORDERS; COMPLICATION; FEMALE; GENETICS; MALE; PREDICTIVE VALUE; PSYCHOLOGY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PREDICTIVE VALUE OF TESTS; PUBMED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84906671789     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (119)

1. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci. 2010;12:393-407.
2. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46.
3. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69:514-519.
4. Awad AG, Voruganti LN. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics. 2012;30:183-195.
5. Lambert M, Schimmelmann BG, Naber D, et al. Early and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. 2009;42:277-283.
6. Boden R, Sundstrom J, Lindstrom E, Lindstrom L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res. 2009;107:232-237.
7. Landolt K, Rossler W, Burns T, et al. The interrelation of needs and quality of life in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2012;262:207-216.
8. Landolt K, Rossler W, Burns T, et al. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychol Med. 2012;42:1461-1473.
9. WHO. Development of the World Health Organization WHOQOLBREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28:551-558.
10. Lehman AF. Measures of quality of life among persons with severe and persistent mental disorders. Soc Psychiatry Psychiatr Epidemiol. 1996;31:78-88.
11. Awad AG, Voruganti LN. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics. 2014;30:183-195.
12. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
13. Potkin SG, Weiden PJ, Loebel AD, et al. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol. 2009;12:1233-1248.
14. Lambert M, Naber D, Karow A, et al. Subjective wellbeing under quetiapine treatment: effect of diagnosis, mood state, and anxiety. Schizophr Res. 2009;110:72-79.
15. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl). 2002;162:3-10.
16. Awad AG. Quality-of-life assessment in schizophrenia: the unfulfilled promise. Expert Rev Pharmacoecon Outcomes Res. 2011;11:491-493.
17. Ware JE Jr, Snow KK, Kosinski MA, Gandek B. SF-36 Health Survey. Manual and Interpretation Guide. Boston, MA: Nimrod Press; 1993.
18. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:5372.
19. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
20. Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LESQ-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005;14:1693-1703.
21. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(suppl 3):133-138.
22. Eack S, Newhill C. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33:1225-37.
23. Vatne S, Bjorkly S. Empirical evidence for using subjective quality of life as an outcome variable in clinical studies A meta-analysis of correlates and predictors in persons with a major mental disorder living in the community. Clin Psychol Rev. 2008;28:869-889.
24. Priebe S, McCabe R, Junghan U, et al. Association between symptoms and quality of life in patients with schizophrenia: a pooled analysis of changes over time. Schizophr Res. 2011;133:17-21.
25. Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L. Schizophrenia and quality of life: how important are symptoms and functioning? Int J Ment Health Syst. 2010;4:31.
26. Meesters PD, Comijs HC, de Haan L, et al. Subjective quality of life and its determinants in a catchment area based population of elderly schizophrenia patients. Schizophr Res. 2011;147:275-280.
27. Carpiniello B, Pinna F, Tusconi M, Zaccheddu E, Fatteri F. Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. Schizophrenia Res Treatment. 2012;2012:576369.
28. Maurino J, Sanjuan J, Haro JM, Diez T, Ballesteros J. Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia. Patient Prefer Adherence. 2011;5:471-474.
29. Dan A, Kumar S, Avasthi A, Grover S. A comparative study on quality of life of patients of schizophrenia with and without depression. Psychiatry Res. 2011;189:185-189.
30. Rocca P, Giugiario M, Montemagni C, et al. Quality of life and psychopathology during the course of schizophrenia. Compr Psychiatry. 2009;50:542-548.
31. Ritsner MS, Grinshpoon A. Ten-year quality of life outcomes of patients with schizophrenia and schizoaffective disorders. Clin Schizophr Relat Psychoses. 2013:1-32.
32. Kumazaki H, Kobayashi H, Niimura H, et al. Lower subjective quality of life and the development of social anxiety symptoms after the discharge of elderly patients with remitted schizophrenia: a 5-year longitudinal study. Compr Psychiatry. 2012;53:946-951.
33. Renwick L, Jackson D, Foley S, et al. Depression and quality of life in first-episode psychosis. Compr Psychiatry. 2012;53:451-455.
34. Ritsner MS, Lisker A, Arbitman M. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors. Qual Life Res. 2014;21:837-847.
35. Meijer CJ, Koeter MW, Sprangers MA, Schene AH. Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2009;44:361-368.
36. Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009;12:536-543.
37. Harvey PD, Sabbag S, Prestia D, et al. Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J Psychiatr Res. 2012;46:1546-1552.
38. Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013;150:339-342.
39. Rabinowitz J, Levine SZ, Garibaldi G, et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147-150.
40. Fujimaki K, Morinobu S, Yamashita H, Takahashi T, Yamawaki S. Predictors of quality of life in inpatients with schizophrenia. Psychiatry Res. 2012;197:199-205.
41. Ojeda N, Sanchez P, Pena J, et al. An explanatory model of quality of life in schizophrenia: the role of processing speed and negative symptoms. Actas Esp Psiquiatr. 2012;40:10-18.
42. Karadayi G, Emiroglu B, Ucok A. Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia. Compr Psychiatry. 2012;52:701-707.
43. Karow A, Naber D, Lambert M, Moritz S; EGOFORS Initiative. Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry. 2011; 27:426-431.
44. Nuechterlein KH, Subotnik KL, Green MF, et al. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull. 2011;37(suppl 2):S33-S40.
45. Reichenberg A, Caspi A, Harrington H, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry. 2010;167:160-169.
46. Green C, Garety PA, Freeman D, et al. Content and affect in persecutory delusions. Br J Clin Psychol. 2006;45:561-577.
47. Kurtz MM, Tolman A. Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: what is their relationship? Schizophr Res. 2010;127:157-162.
48. Boyer L, Aghababian V, Richieri R, et al. Insight into illness, neurocognition and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:271-276.
49. Maat A, Fett AK, Derks E. Social cognition and quality of life in schizophrenia. Schizophr Res. 2012;137:212-218.
50. Urbach M, Brunet-Gouet E, Bazin N, Hardy-Bayle MC, Passerieux C. Correlations of theory of mind deficits with clinical patterns and quality of life in schizophrenia. Front Psychiatry. 2013;4:30.
51. Switaj P, Wciorka J, Smolarska-Switaj J, Grygiel P. Extent and predictors of stigma experienced by patients with schizophrenia. Eur Psychiatry. 2009;24:513-520.
52. Ucok A, Karadayi G, Emiroglu B, Sartorius N. Anticipated discrimination is related to symptom severity, functionality and quality of life in schizophrenia. Psychiatry Res. 2013;209:333-339.
53. Tang IC, Wu HC. Quality of life and self-stigma in individuals with schizophrenia. Psychiatr Q. 2012;83:497-507.
54. van Baars AW, Wierdsma AI, Hengeveld MW, Mulder CL. Improved insight affects social outcomes in involuntarily committed psychotic patients: a longitudinal study in the Netherlands. Compr Psychiatry. 2013;54:873-879.
55. Karow A, Pajonk FG, Reimer J, et al. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur Arch Psychiatry Clin Neurosci. 2007;258:152-159.
56. Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2012;38:304-315.
57. Andreasen NC, Carpenter WT, Jr., Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
58. Brissos S, Dias VV, Balanza-Martinez V, Carita AI, Figueira ML. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res. 2011;129:133-136.
59. Haynes VS, Zhu B, Stauffer VL, et al. Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry. 2012;12:222.
60. Docherty JP, Bossie CA, Lachaux B, et al. Patient-based and clinicianbased support for the remission criteria in schizophrenia. Int Clin Psychopharmacol. 2007;22:51-55.
61. Lambert M, Naber D, Eich FX, et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand. 2007;115:106-113.
62. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41:125-128
63. Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry. 2010;25:220-229.
64. Lambert M, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118:220-229.
65. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690-1697.
66. Bobes J, Ciudad A, Alvarez E, et al. Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophr Res. 2009;115:58-66.
67. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res. 2007;93:160-168.
68. Cohen CI, Pathak R, Ramirez PM, Vahia I. Outcome among community dwelling older adults with schizophrenia: results using five conceptual models. Community Ment Health J. 2009;45:151-156.
69. Schennach-Wolff R, Jager M, Seemuller F, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009;113:210-217
70. Karow A, Moritz S, Lambert M, Schottle D, Naber D. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry. 2012;27:401-405.
71. Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology. 2005;38:320-326.
72. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51:171-180.
73. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65:932-939.
74. Hofer A, Rettenbacher MA, Widschwendter CG, et al. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci. 2006;256:246-255.
75. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: patient report outcome measures: use in clinical medical product development to support labelling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
76. Hofer A, Rettenbacher MA, Edlinger M, et al. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry. 2007;40:1-8.
77. Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol. 2005;15:249-258.
78. Putzhammer A, Perfahl M, Pfeiff L, Hajak G. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry. 2005;38:132-138.
79. DeHaan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale [Medico-economic study of Leponex (clozapine) in the Bordeaux Charles Perrens Hospital Center]. Psychopharmacology (Berl). 2002;162:24-28.
80. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry. 2007;68:75-80.
81. Sugawara N, Yasui-Furukori N, Sato Y, et al. Body mass index and quality of life among outpatients with schizophrenia in Japan. BMC Psychiatry. 2013;13:108.
82. Yeh CB, Huang YS, Tang CS, et al. Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia. Nord J Psychiatry. 2013;68:219-224.
83. Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 2006;10:iii-iv,ix-xi,1-165.
84. Fujimaki K, Takahashi T, Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS One. 2012;7:e37087.
85. Hayhurst KP, Drake RJ, Massie JA, et al. Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry. 2013;29:191-196.
86. Barnes TR, Drake RJ, Dunn G, et al. Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes. Br J Psychiatry. 2013;203:215-220.
87. Harvey PD, Pappadopulos E, Lombardo I, Kremer CM. Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. Schizophr Res. 2009;115:24-29.
88. Awad AG, Voruganti LN. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs. 2013;27:625-636.
89. Penn DL, Uzenoff SR, Perkins D, et al. A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis. Schizophr Res. 2011;125:247-256.
90. Pitkanen A, Valimaki M, Kuosmanen L, et al. Patient education methods to support quality of life and functional ability among patients with schizophrenia: a randomised clinical trial. Qual Life Res. 2012;21:247-256.
91. Vancampfort D, Vansteelandt K, Scheewe T, et al. Yoga in schizophrenia: a systematic review of randomised controlled trials. Acta Psychiatr Scand. 2012;126:12-20.
92. Vancampfort D, Knapen J, Probst M, et al. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012;125:352-362.
93. Schöttle D, Karow A, Schimmelmann BG, Lambert M. Integrated care in patients with schizophrenia: results of trials published between 2011 and 2013 focusing on effectiveness and efficiency. Curr Opin Psychiatry. 2013;26:384-408.
94. Lambert M, Bock T, Schottle D, et al. Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS Trial). J Clin Psychiatry. 2010;71:1313-1323.
95. Stein LI, Santos AB. Assertive Community Treatment of Persons with Severe Mental Illness. New York, NY: WW Norton & Company Inc; 2000.
96. Marshall M, Lockwood A. WITHDRAWN: Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev. 2011:CD001089.
97. Teague GB, Mueser KT, Rapp CA. Advances in fidelity measurement for mental health services research: four measures. Psychiatr Serv. 2012;63:765-771.
98. Asserrive Cimmunity Treatment Association (ACTA). Available at: http://www.actassociation.org. Accessed April 28, 2014.
99. Karow A, Reimer J, Konig HH, et al. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2012;73:e402-408.
100. Addington DE, McKenzie E, Wang J. Validity of hospital admission as an outcome measure of services for first-episode psychosis. Psychiatr Serv. 2012;63:280-282.
101. Chang LR, Lin YH, Kuo TB, et al. Autonomic modulation and healthrelated quality of life among schizophrenic patients treated with nonintensive case management. PLoS One. 2013;6:e26378.
102. Boyer L, Lancon C, Baumstarck K, et al. Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial. Br J Psychiatry. 2013;202:447-453.
103. Eklund M. Work status, daily activities and quality of life among people with severe mental illness. Qual Life Res. 2009;18:163-170.
104. Schroeder K, Huber CG, Jelinek L, Moritz S. Subjective well-being, but not subjective mental functioning shows positive associations with neuropsychological performance in schizophrenia-spectrum disorders. Compr Psychiatry. 2012;54:824-830.
105. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull. 2007;33:792-796.
106. Chen EY, Tang JY, Hui CL, et al. Three-year outcome of phase-specific early intervention for first-episode psychosis: a cohort study in Hong Kong. Early Interv Psychiatry. 2011;5:315-323.
107. Peuskens J, Gorwood P. How are we assessing functioning in schizophrenia? A need for a consensus approach. Eur Psychiatry. 2012;27:391-395.
108. Naber D, Kollack-Walker S, Chen J, et al. Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being. Pharmacopsychiatry. 2013;46:114-119.
109. Chou KR, Shih YW, Chang C, et al. Psychosocial rehabilitation activities, empowerment, and quality of community-based life for people with schizophrenia. Arch Psychiatr Nurs. 2012;26:285-294.
110. Marchinko S, Clarke D. The Wellness Planner: empowerment, quality of life, and continuity of care in mental illness. Arch Psychiatr Nurs. 2011;25:284-293.
111. Cohen CI, Hassamal SK, Begum N. General coping strategies and their impact on quality of life in older adults with schizophrenia. Schizophr Res. 2011;127:223-228.
112. Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health. 2012;14:907-920.
113. Briand C, Vasiliadis HM, Lesage A, et al. Including integrated psychological treatment as part of standard medical therapy for patients with schizophrenia: clinical outcomes. J Nerv Ment Dis. 2006;194:463-470.
114. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006;36:1349-1362.
115. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry. 1999;45:7-12.
116. Lehman AF. A quality of life interview for the chronically mental ill. Evaluation Program Plann. 1988;11:51-62.
117. Oliver JP, Huxley PJ, Priebe S, Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol. 1997;32:76-83.
118. Boyer L, Simeoni MC, Loundou A, et al. The development of the SQoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr Res. 2010;121:241-250.
119. Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177:42-46.